Research ExplorerPublicationsRetransplantation with stem cells from mismatched related do...

Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients

Standard

Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. / Lang, Peter; Müller, Ingo; Greil, Johann; Bader, Peter; Schumm, Michael; Pfeiffer, Matthias; Hoelle, Walter; Klingebiel, Thomas; Heinzelmann, Frank; Belka, Claus; Schlegel, Paul G; Kremens, Bernhard; Woessmann, Wilhelm; Handgretinger, Rupert.

In: BLOOD CELL MOL DIS, Vol. 40, No. 1, 22.09.2007, p. 33-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lang, P, Müller, I, Greil, J, Bader, P, Schumm, M, Pfeiffer, M, Hoelle, W, Klingebiel, T, Heinzelmann, F, Belka, C, Schlegel, PG, Kremens, B, Woessmann, W & Handgretinger, R 2007, 'Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients', BLOOD CELL MOL DIS, vol. 40, no. 1, pp. 33-9. https://doi.org/10.1016/j.bcmd.2007.06.027

APA

Lang, P., Müller, I., Greil, J., Bader, P., Schumm, M., Pfeiffer, M., Hoelle, W., Klingebiel, T., Heinzelmann, F., Belka, C., Schlegel, P. G., Kremens, B., Woessmann, W., & Handgretinger, R. (2007). Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. BLOOD CELL MOL DIS, 40(1), 33-9. https://doi.org/10.1016/j.bcmd.2007.06.027

Vancouver

Lang P, Müller I, Greil J, Bader P, Schumm M, Pfeiffer M et al. Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. BLOOD CELL MOL DIS. 2007 Sep 22;40(1):33-9. https://doi.org/10.1016/j.bcmd.2007.06.027

Bibtex

@article{16bc2b5e23bb4631922b80336a4249b1,
title = "Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients",
abstract = "Graft failure is a life-threatening complication after transplantation of hematopoietic stem cells. We report a cohort of 11 pediatric patients with leukemias (n=8) and severe aplastic anemia (n=3) who experienced graft rejection after myeloablative transplantation from mismatched related donors (n=6) or after cord blood or matched unrelated donor transplantation (n=5). In the latter, the original donor was not available anymore. All patients were re-transplanted with CD34(+) selected or CD3/CD19 depleted stem cells from a second, haploidentical donor. Median time span from diagnosis of rejection to second transplant was 9 days. Reconditioning regimens comprised total lymphoid irradiation, thiotepa, fludarabine, ATG/OKT3 and were well tolerated. A median number of 23.5x10(6)/kg stem cells with 95,000/kg residual T-cells were infused. Sustained engraftment of neutrophiles/platelets and complete donor chimerism was achieved in all patients (ANC>500/microl: 9 (11-32) days). No GvHD>grade II was observed. 8/11 patients are disease free (median follow up 1.9 years; 1 year-EFS=72%). Causes of death were: pneumonitis, infection, relapse. Thus, haploidentical transplantation represents a realistic option to rescue patients with graft failure within a short time span, for whom a second donation from the original donor is not available. The use of different donors may contribute to avoid a second rejection.",
keywords = "Adolescent, Adult, Cause of Death, Cell Count, Cell Separation, Child, Child, Preschool, Cohort Studies, Disease-Free Survival, Graft Rejection, Graft Survival, Haplotypes, Hematopoietic Stem Cell Transplantation, Histocompatibility, Humans, Leukocyte Reduction Procedures, Reoperation, Transplantation Chimera, Transplantation Conditioning, Transplantation, Homologous",
author = "Peter Lang and Ingo M{\"u}ller and Johann Greil and Peter Bader and Michael Schumm and Matthias Pfeiffer and Walter Hoelle and Thomas Klingebiel and Frank Heinzelmann and Claus Belka and Schlegel, {Paul G} and Bernhard Kremens and Wilhelm Woessmann and Rupert Handgretinger",
year = "2007",
month = sep,
day = "22",
doi = "10.1016/j.bcmd.2007.06.027",
language = "English",
volume = "40",
pages = "33--9",
journal = "BLOOD CELL MOL DIS",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients

AU - Lang, Peter

AU - Müller, Ingo

AU - Greil, Johann

AU - Bader, Peter

AU - Schumm, Michael

AU - Pfeiffer, Matthias

AU - Hoelle, Walter

AU - Klingebiel, Thomas

AU - Heinzelmann, Frank

AU - Belka, Claus

AU - Schlegel, Paul G

AU - Kremens, Bernhard

AU - Woessmann, Wilhelm

AU - Handgretinger, Rupert

PY - 2007/9/22

Y1 - 2007/9/22

N2 - Graft failure is a life-threatening complication after transplantation of hematopoietic stem cells. We report a cohort of 11 pediatric patients with leukemias (n=8) and severe aplastic anemia (n=3) who experienced graft rejection after myeloablative transplantation from mismatched related donors (n=6) or after cord blood or matched unrelated donor transplantation (n=5). In the latter, the original donor was not available anymore. All patients were re-transplanted with CD34(+) selected or CD3/CD19 depleted stem cells from a second, haploidentical donor. Median time span from diagnosis of rejection to second transplant was 9 days. Reconditioning regimens comprised total lymphoid irradiation, thiotepa, fludarabine, ATG/OKT3 and were well tolerated. A median number of 23.5x10(6)/kg stem cells with 95,000/kg residual T-cells were infused. Sustained engraftment of neutrophiles/platelets and complete donor chimerism was achieved in all patients (ANC>500/microl: 9 (11-32) days). No GvHD>grade II was observed. 8/11 patients are disease free (median follow up 1.9 years; 1 year-EFS=72%). Causes of death were: pneumonitis, infection, relapse. Thus, haploidentical transplantation represents a realistic option to rescue patients with graft failure within a short time span, for whom a second donation from the original donor is not available. The use of different donors may contribute to avoid a second rejection.

AB - Graft failure is a life-threatening complication after transplantation of hematopoietic stem cells. We report a cohort of 11 pediatric patients with leukemias (n=8) and severe aplastic anemia (n=3) who experienced graft rejection after myeloablative transplantation from mismatched related donors (n=6) or after cord blood or matched unrelated donor transplantation (n=5). In the latter, the original donor was not available anymore. All patients were re-transplanted with CD34(+) selected or CD3/CD19 depleted stem cells from a second, haploidentical donor. Median time span from diagnosis of rejection to second transplant was 9 days. Reconditioning regimens comprised total lymphoid irradiation, thiotepa, fludarabine, ATG/OKT3 and were well tolerated. A median number of 23.5x10(6)/kg stem cells with 95,000/kg residual T-cells were infused. Sustained engraftment of neutrophiles/platelets and complete donor chimerism was achieved in all patients (ANC>500/microl: 9 (11-32) days). No GvHD>grade II was observed. 8/11 patients are disease free (median follow up 1.9 years; 1 year-EFS=72%). Causes of death were: pneumonitis, infection, relapse. Thus, haploidentical transplantation represents a realistic option to rescue patients with graft failure within a short time span, for whom a second donation from the original donor is not available. The use of different donors may contribute to avoid a second rejection.

KW - Adolescent

KW - Adult

KW - Cause of Death

KW - Cell Count

KW - Cell Separation

KW - Child

KW - Child, Preschool

KW - Cohort Studies

KW - Disease-Free Survival

KW - Graft Rejection

KW - Graft Survival

KW - Haplotypes

KW - Hematopoietic Stem Cell Transplantation

KW - Histocompatibility

KW - Humans

KW - Leukocyte Reduction Procedures

KW - Reoperation

KW - Transplantation Chimera

KW - Transplantation Conditioning

KW - Transplantation, Homologous

U2 - 10.1016/j.bcmd.2007.06.027

DO - 10.1016/j.bcmd.2007.06.027

M3 - SCORING: Journal article

C2 - 17884640

VL - 40

SP - 33

EP - 39

JO - BLOOD CELL MOL DIS

JF - BLOOD CELL MOL DIS

SN - 1079-9796

IS - 1

ER -